RCT: Pembrolizumab vs. placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma.
4 Apr, 2022 | 00:56h | UTCPembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial – The Lancet (link to abstract – $ for full-text)